Robert Nelsen has bought stock on 7 days since Jul 2016

Robert Nelsen is a co-founder and Managing Director of ARCH Venture Partners, a venture capital firm he joined at its founding in 1994( Throughout his career, he has played a significant role in the early sourcing, financing, and development of more than 150 companies, including 38-39 that have reached valuations exceeding $1 billion( His notable early-stage investments span transformative biotechnology and life sciences companies, including Illumina, Alnylam Pharmaceuticals, Juno Therapeutics, Beam Therapeutics, Karuna Therapeutics, Altos Labs, National Resilience, Insitro, and Vir Biotechnology( Nelsen focuses on disruptive technologies and business models, partnering with founding management teams and entrepreneurs to advance novel platform technologies with the goal of improving healthcare outcomes(

Nelsen currently serves as a director of multiple biotechnology and biopharmaceutical companies, including Prime Medicine, Lyell Immunopharma, Vir Biotechnology, Sana Biotechnology, Beam Therapeutics, National Resilience, and others, while also serving as Chairman of Hua Medicine( He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute and the Institute of Systems Biology, and as a director of the National Venture Capital Association( Nelsen holds an M.B.A. from the University of Chicago Booth School of Business and a B.S. from the University of Puget Sound with majors in Economics and Biology(

Written by Perplexity from public sources.